GWPH

EPIDIOLEX® (cannabidiol)

Tuberous Sclerosis Complex

Quarterly Sales (Approved)

Exp Date

February 26, 2021 (Est)

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: EPIDIOLEX® (cannabidiol) for Tuberous Sclerosis Complex - Quarterly Sales (Approved)


WHAT IS THE CATALYST EVENT?

  • Quarterly Sales (Approved)


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • February 26, 2021 (Est)


PRIOR DATA/EVENTS

PRESS RELEASE

List last quarter's sales e.g. $137.1 million Q3/2020

2020 Revenue guidance: NOT PROVIDED by company

MECHANISM OF ACTION

  • The precise mechanisms by which EPIDIOLEX exerts its anticonvulsant effect in humans are unknown. Cannabidiol does not appear to exert its anticonvulsant effects through interaction with cannabinoid receptors.

Updated by HC

GWPH, Tuberous Sclerosis Complex, EPIDIOLEX® (cannabidiol), genetic disorder, noncancerous (benign) tumors

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon